Peramivir tests revived

摘要

Safety and efficacy trials for the neu-raminidase inhibitor peramivir are starting this spring,BioCryst Pharmaceuticals director of peramivir development Shane Arnold,told the Bird Flu Summit held in Washington,DC,this week.The antiviral has been shown to be effective in animals in inhibiting both influenza A and B neuraminidases.